ICLE 2022 | Focusing on allogeneic CAR T-cell therapies for myeloma
Tuna Mutis
• 1 Apr 2022
Tuna Mutis, MD, PhD, Amsterdam University Medical Center, Amsterdam, The Netherlands, discusses the advantages of using allogeneic sources for chimeric antigen receptor (CAR) T-cell therapy, especially for the treatment of multiple myeloma. Patients with myeloma tend to be older and as result of their age and disease status, the T-cells will be dysfunctional and unsuitable for the production of CAR T-cell therapies. Allogeneic T-cells will enhance the efficacy of cell therapies and additionally reduce production costs. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
